Findings from the first-ever prospective trial including a randomized pathway comparing surgery to non-surgical treatment of malignant bowel obstruction (MBO) provide evidence to inform clinical decision-making in managing this frequent complication in patients with advanced cancer.
A new report says those considering PSA screening need such quantitative information on risks and benefits of treatment if they are to make truly informed decisions. Yet leading guidelines do not provide specific estimates of risk. The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years after...
